Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

2.010 +0.090 (+4.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,225,329
Open 1.900
Bid (Size) 2.010 (200)
Ask (Size) 2.040 (400)
Prev. Close 1.920
Today's Range 1.890 - 2.090
52wk Range 1.300 - 3.480
Shares Outstanding 61,540,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the... 
From ProKidney
Via GlobeNewswire

Performance

YTD
-9.9%
-9.9%
1 Month
+20.4%
+20.4%
3 Month
+11.7%
+11.7%
6 Month
-12.6%
-12.6%
1 Year
-12.6%
-12.6%

More News

Read More
News headline image
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Corp (NASDAQ:PROK) Reports Q3 2025 Earnings and Clinical Progress ↗
Via Chartmill
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
Via MarketMinute
News headline image
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
From ProKidney
Via GlobeNewswire
News headline image
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC ↗
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% ↗
Via Benzinga
News headline image
ProKidney Reports 78 Percent Gain in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss ↗
Via Chartmill
News headline image
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
From ProKidney
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Rocketed 775% Higher ↗
Via The Motley Fool
News headline image
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? ↗
Via The Motley Fool
News headline image
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill

Frequently Asked Questions

Is ProKidney Corp. - Class A Ordinary Shares publicly traded?
Yes, ProKidney Corp. - Class A Ordinary Shares is publicly traded.
What exchange does ProKidney Corp. - Class A Ordinary Shares trade on?
ProKidney Corp. - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProKidney Corp. - Class A Ordinary Shares?
The ticker symbol for ProKidney Corp. - Class A Ordinary Shares is PROK on the Nasdaq Stock Market
What is the current price of ProKidney Corp. - Class A Ordinary Shares?
The current price of ProKidney Corp. - Class A Ordinary Shares is 2.010
When was ProKidney Corp. - Class A Ordinary Shares last traded?
The last trade of ProKidney Corp. - Class A Ordinary Shares was at 09/04/26 04:00 PM ET
What is the market capitalization of ProKidney Corp. - Class A Ordinary Shares?
The market capitalization of ProKidney Corp. - Class A Ordinary Shares is 123.70M
How many shares of ProKidney Corp. - Class A Ordinary Shares are outstanding?
ProKidney Corp. - Class A Ordinary Shares has 124M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.